UK surrogacy: medical screening and donor requirements
The decision in brief
UK surrogacy does not have a single statutory checklist that automatically qualifies a surrogate, egg provider, sperm provider and intended parents. Instead, licensed fertility treatment engages the Human Fertilisation and Embryology Acts, HFEA licence conditions and clinical assessment; a clinic also has its own evidence-based acceptance criteria. Screening and valid consent must be addressed before treatment, but a positive medical assessment does not establish legal parenthood or guarantee a court order. Ask two questions separately: can the proposed people and reproductive material safely be treated by this clinic, and can the intended parent or parents later obtain the legal status they need? This guide concerns UK treatment and donor requirements, with England-and-Wales operational guidance identified where relevant. It is not a universal medical clearance or a substitute for individual advice.
What the law regulates, and what the clinic decides
The HFEA licenses and regulates specified fertility activities, not every aspect of a private surrogacy arrangement. The Human Fertilisation and Embryology Act 1990, including Schedule 3, controls consents for use and storage of gametes and embryos; the 2008 Act governs important parenthood consequences. HFEA licence requirements, directions and the Code of Practice inform licensed-centre duties. Separately, a clinic decides whether a particular pregnancy or treatment is medically appropriate after reviewing examinations, fertility history, infection results and risks. Its age bands, previous-birth preferences, body-mass-index thresholds and other criteria must not be presented as universal statutory bans without identifying a law. Ask the clinic to identify whether each refusal arises from legislation, a binding licence requirement, professional guidance or its own protocol.
Gestational and traditional surrogacy: whose eggs are used?
In gestational or host surrogacy the surrogate carries an embryo made with an intended parent's or donor's egg; she is not genetically related to the child. Creation and transfer of that embryo ordinarily involve IVF; ICSI may be clinically indicated. In traditional or straight surrogacy the surrogate's egg is used, sometimes with insemination. The HFEA recommends a licensed clinic rather than unscreened home insemination, which carries infection and legal-parenthood risks. Neither route itself transfers legal motherhood: the person giving birth is the legal mother at birth under the UK framework. The chosen combination of egg, sperm and carrier affects screening, consent, treatment technique and the later parental-order route. It is therefore unsafe to select donors before checking both the medical pathway and the intended parenthood outcome.
Donor combinations and the genetic-link trap
A donor egg may be used with sperm from an intended parent; donor sperm may be used with an intended parent's egg; embryos may also involve donated material subject to treatment and consent rules. However, for the statutory UK parental-order route under sections 54 and 54A of the 2008 Act, at least one applicant must have provided an egg or sperm used to create the child. Two unrelated donors therefore may permit a clinically assessed embryo-transfer proposal yet leave intended parents unable to meet that genetic-link condition for a parental order. The child's legal status is not resolved merely because a clinic agrees to the procedure. Where neither intended parent can provide gametes, obtain specialist parentage advice about any other lawful pathway before fertilisation, not after birth.
Screening of egg and sperm providers
HFEA information states that a surrogate's egg and sperm providers must be screened before treatment because infection can be transmitted to the carrier. People supplying gametes for surrogacy through a clinic are assessed in line with donor screening requirements; clinics evaluate medical and family history and relevant infectious-disease and genetic risks. The official England-and-Wales pathway mentions hepatitis B, hepatitis C and HIV testing, additional tests where travel or health history warrants them, and semen analysis where applicable. The precise panel, timing, repeat testing and any quarantine arrangements depend on current rules, sample type and clinic protocol; Official guidance describes a six-month quarantine as usual in one pathway, but that is not a universal waiting period for every material or method. Obtain a written test schedule for every genetic contributor, including a known donor.
The surrogate's medical suitability
A surrogate should receive an individual assessment of whether carrying a pregnancy is medically appropriate. A clinic may consider prior pregnancies and births, obstetric complications, underlying conditions, medicines, infection risks, mental wellbeing, and whether IVF medication or embryo transfer creates unacceptable danger. HFEA notes that pregnancy risks may increase over age 35, but that observation is not a general statutory maximum surrogate age. Likewise, a clinic's requirements for previous uncomplicated births, BMI or psychological review must be verified as that clinic's criteria unless a specific binding rule is identified. Pregnancy and treatment entail risks, including miscarriage, ectopic pregnancy and multiple birth. A favourable review reduces uncertainty; it does not promise pregnancy or delivery.
Known donors, licensed clinics and imported gametes
A friend or family member may be a known egg or sperm donor, but known status does not remove the need for a licensed clinic's screening, information and appropriate consent procedures. HFEA explains that treatment with clinic-screened donors is substantially different from informal or home arrangements, especially for infection and donor legal status. Clinics may obtain donations from UK banks or import sperm, eggs or embryos only through an appropriately licensed service meeting applicable import conditions. Do not assume that overseas donor documents, anonymous status or a foreign screening certificate automatically satisfy UK requirements. Before purchasing or shipping material, ask the receiving clinic whether it can lawfully accept that source and which evidence and consents must accompany it.
Consent must precede the relevant treatment
Written, effective consent is central, not an administrative formality. Schedule 3 of the 1990 Act requires relevant permissions for use and storage of gametes and embryos, with counselling opportunities and information before consent; circumstances permitting variation or withdrawal depend on what has already been done. Clinics should explain treatment, donation, use and storage, intended recipients, possible death or loss of capacity, and consequences of withdrawing consent. Where relevant, separate HFEA parenthood consents may be needed before insemination or embryo transfer, including the surrogate's designation of a second legal parent. Forms and signatures should be matched to the actual participants and treatment. A surrogacy agreement is not a substitute for medical consent or a court's later decision.
Counselling and welfare review
The clinic must provide the appropriate information and an opportunity for counselling about the implications of treatment. HFEA guidance emphasises discussions individually and together where appropriate: medical and psychological risks to the surrogate, impacts on partners and family, donor origins, the possibility of treatment failing, and what happens if intended parents do not proceed to parent the child. Licensed centres also consider the welfare of a child who may be born, as required under the 1990 Act's treatment framework. These steps support informed and voluntary decisions; they should not be confused with a blanket legal rule that every surrogate must pass one prescribed psychological score or use a particular counsellor.
HIV and other findings are not always automatic exclusions
Screening is necessary, but a positive finding does not automatically answer whether a person can supply gametes. HFEA's updated guidance permits certain donation by people living with HIV who maintain an undetectable viral load and satisfy the relevant conditions. It specifically explains that intended parents supplying gametes in a surrogacy arrangement may fall within that pathway because the surrogate knows them. The clinic must assess the applicable health checks and conditions in the individual case; this does not waive other screening or make every HIV-positive donation eligible. For any abnormal result, request the clinic's precise legal or medical reason, whether further tests or treatment can address it, and whether a second specialist opinion is appropriate. The HFEA specifies an HIV viral-load limit of 200 copies/mL or less, antiretroviral treatment throughout the preceding six months, and two blood tests: one between six months and 21 days before providing eggs or sperm, and another no more than seven days before. This route is for known recipients, not anonymous donation; the surrogate must understand the HIV finding and consent to treatment on that basis. Previously stored embryos may not meet these timing rules: ask the clinic before using them.
Storage, timing and treatment choices
If gametes or embryos are frozen, check each contributor's storage consent, stated purpose and duration, renewal requirements and any posthumous-use instructions. The fact that material is physically stored does not prove it can legally be used for a new recipient, surrogate or changed plan. Discuss whether IVF, ICSI or insemination is clinically indicated and how success chances depend on egg age, sperm quality and the surrogate's health. Ask about repeat infectious screening, embryo-transfer approach, multiple-pregnancy prevention and what happens if no suitable embryo is available. Treatment cost and success estimates are clinic-specific, not statutory entitlement. Obtain a dated written plan before commencing medication or transferring embryos. Consent is not irrevocable just because an embryo has been created. A provider's withdrawal before the embryo is used in treatment can prevent transfer. In September 2026, the HFEA clarified that, where the statutory 12-month cooling-off period is triggered by withdrawal, affected embryos may remain stored during that period but cannot be used without effective consent; the clinic must address disposal once the period ends. Where paragraph 4A of Schedule 3 to the 1990 Act applies, the 12 months run from receipt of the withdrawal notice by the person storing the embryo; the period ends sooner if every notified interested person consents to its destruction. Obtain written, case-specific confirmation of the applicable withdrawal and storage rule.
Medical approval is not a parental order
Even where the surrogate is unrelated genetically, she is the child's legal mother at birth; a second legal parent may be determined by marital status, treatment consents and other facts. Sections 54 and 54A of the 2008 Act set conditions for parental orders, including a genetic link with at least one applicant. Further conditions concern applicants, the child's home, domicile, consents after birth and the court's review of payments. A surrogate's consent to the order generally cannot be effective if given less than six weeks after birth. These matters require a separate legal assessment; do not assume that signed clinic forms, DNA results or a foreign birth certificate directly transfer parenthood. Scottish and Northern Irish court procedures differ from England and Wales; cross-border cases add further complications.
Three decisions that change the answer
Scenario A: one intended parent supplies sperm and a screened donor supplies eggs. The proposed gestational IVF route may be considered clinically, and the parental-order genetic-link requirement may be met; other court conditions still matter. Scenario B: two unrelated donors supply both gametes. Even if a clinic could treat the carrier, the intended parents would not satisfy that genetic-link condition, so they need specific legal advice before proceeding. Scenario C: a known intended-parent gamete provider has an abnormal screening result. The result triggers clinical review, not necessarily a universal lifetime ban; the outcome depends on the precise condition, the applicable rules and available safeguards. In every scenario, medical permission, valid consent and later legal parenthood remain separate checkpoints.
Documents and next steps before treatment
Prepare an identity and relationship record for everyone involved; a written chart of whose egg, sperm and uterus will be used; relevant fertility, pregnancy and medical histories; laboratory and genetic-screening reports; donor identity and provenance; draft clinic consent and counselling records; and storage or import paperwork if applicable. Request the clinic's HFEA licence details, its written surrogate/donor acceptance criteria, a reasoned answer to any refusal, a screening and repeat-test timetable, its embryo and consent plan, and expected charges. Independently ask a UK surrogacy lawyer whether the chosen gamete combination meets the parental-order genetic-link rule and what birth and consent events must be documented. Pause before procuring gametes or creating embryos if either the clinical route or post-birth status is unresolved.
Official sources
- HFEA — Surrogacy
- HFEA — Surrogacy factsheet
- Human Fertilisation and Embryology Act 1990, Schedule 3
- DHSC — The surrogacy pathway (England and Wales)
- Human Fertilisation and Embryology Act 2008, section 54
- 2018 Remedial Order introducing section 54A
- HFEA — Using donated eggs, sperm or embryos
- HFEA — Consent to treatment and storage
- HFEA — Donation involving HIV and an undetectable viral load
- HFEA — Home insemination with donor sperm
- Human Fertilisation and Embryology Act 1990, current consolidated text
- HFEA — Withdrawal of consent after embryo creation (21 September 2026)
